首页> 外文期刊>Orphanet journal of rare diseases >Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency
【24h】

Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency

机译:芳香族l-氨基酸脱羧酶(AADC)缺乏症的诊断和治疗共识指南

获取原文
           

摘要

Aromatic L-amino acid decarboxylase deficiency (AADCD) is a rare, autosomal recessive neurometabolic disorder that leads to a severe combined deficiency of serotonin, dopamine, norepinephrine and epinephrine. Onset is early in life, and key clinical symptoms are hypotonia, movement disorders (oculogyric crisis, dystonia, and hypokinesia), developmental delay, and autonomic symptoms.In this consensus guideline, representatives of the International Working Group on Neurotransmitter Related Disorders (iNTD) and patient representatives evaluated all available evidence for diagnosis and treatment of AADCD and made recommendations using SIGN and GRADE methodology. In the face of limited definitive evidence, we constructed practical recommendations on clinical diagnosis, laboratory diagnosis, imaging and electroencephalograpy, medical treatments and non-medical treatments. Furthermore, we identified topics for further research. We believe this guideline will improve the care for AADCD patients around the world whilst promoting general awareness of this rare disease.
机译:芳香族L-氨基酸脱羧酶缺乏症(AADCD)是一种罕见的常染色体隐性神经代谢疾病,可导致5-羟色胺,多巴胺,去甲肾上腺素和肾上腺素的严重联合缺乏症。发病是生命的早期,关键的临床症状是肌张力低下,运动障碍(眼科疾病,肌张力障碍和运动不足),发育迟缓和植物神经系统症状。在该共识指南中,神经递质相关疾病国际工作组(iNTD)的代表患者代表评估了所有可用于AADCD诊断和治疗的证据,并使用SIGN和GRADE方法提出了建议。面对有限的确凿证据,我们针对临床诊断,实验室诊断,影像学和脑电疗法,药物治疗和非药物治疗提出了实用建议。此外,我们确定了需要进一步研究的主题。我们相信,该指南将改善世界各地对AADCD患者的护理,同时提高对这种罕见疾病的普遍认识。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号